Cerity Partners’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Cerity Partners’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$40.5K	Hold	163,943	–	–	﹤0.01%	3128
2025 Q4	$68.9K	Sell	163,943 -15,725	-9%	-$8.34K	﹤0.01%	2789
2025 Q3	$121K	Buy	179,668 +129,668	+259%	+$69.9K	﹤0.01%	2605
2025 Q2	$27.1K	Sell	50,000 -5,000	-9%	-$2.97K	﹤0.01%	2596
2025 Q1	$36.1K	Buy	55,000 +44,800	+439%	+$47.4K	﹤0.01%	2419
2024 Q4	$10.4K	Buy	10,200 +200	+2%	+$366	﹤0.01%	2413
2024 Q3	$8.66K	Hold	10,000	–	–	﹤0.01%	2519
2024 Q2	$3.58K	Hold	10,000	–	–	﹤0.01%	2216
2024 Q1	$6.7K	Hold	10,000	–	–	﹤0.01%	2278
2023 Q4	$5.43K	Buy	+10,000	New	+$4.61K	﹤0.01%	1846

Other funds holding SGMO

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Cerity Partners's SGMO Position: Q1 2026 in Review

Cerity Partners held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q1 2026 at 163,943 shares worth $40.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3128.

Cerity Partners first reported a position in SGMO in Q4 2023 and has held it in 10 quarters since. The position peaked at $121K in Q3 2025. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

Cerity Partners held 163,943 shares of SANGAMO THERAPEUTICS INC worth $40.5K as of Q1 2026.
Cerity Partners left its SANGAMO THERAPEUTICS INC share count unchanged in Q1 2026.
SANGAMO THERAPEUTICS INC made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #3128 holding.
Cerity Partners first reported a position in SANGAMO THERAPEUTICS INC in Q4 2023 and has held it in 10 quarters since.
Cerity Partners's SANGAMO THERAPEUTICS INC position peaked at $121K in Q3 2025.
112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.